SCHEMBL25634773

SCHEMBL25634773

CC(=O)OC[C@H]1O[C@H](Oc2ccc(CO)cc2N)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.42
▸ CYP3A4 P08684 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ CASP1 P29466 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ ACHE P22303 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ LMNA P02545 1/20 0.40
▸ P4HB P07237 1/20 0.40
▸ PDIA4 P13667 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799426 0.92 HSD17B10 (0.50) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL13942270 0.92 HSD17B10 (0.50) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL22631568 0.92 HSD17B10 (0.50) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL27214337 0.92 HSD17B10 (0.50) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL13899513 0.92 HSD17B10 (0.50) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL17798578 0.92 HSD17B10 (0.50) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL25633170 0.92 HSD17B10 (0.50) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL21569127 0.87 CYP3A4 (0.45) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL24455470 0.83 CYP2D6 (0.50) MEN1CYP3A4KMT2AHSD17B10TP53
SCHEMBL24455282 0.83 CYP2D6 (0.50) MEN1CYP3A4KMT2AHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230173093-A1 CHARGE VARIANT LINKERS SEAGEN INC (US) 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230173093-A1 CHARGE VARIANT LINKERS SSB, UACA, CDA MEN1 515/4885CYP3A4 4396/4885KMT2A 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback